mRNA vaccine against SARS-CoV-2 developed by Moderna. mRNA vaccine against SARS-CoV-2, developed by Moderna.
PUBLIÉ LE 18/02/2022 https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-la-covid-19-periode-du-28-01-2022-au-10-02-2022 2022 false false false France French mRNA Vaccine mRNA Vaccines 2019-nCoV Vaccine mRNA-1273 BNT162 Vaccine drug information pharmacovigilance adverse drug reaction reporting systems france vaccination Drug-Related side effects and adverse reactions drug monitoring mRNA vaccine Administration of vaccine product containing only severe acute respiratory syndrome
coronavirus 2 antigen (procedure) Covid-19 vaccines COVID-19 COVID-19 Vaccines
--- PUBLIÉ LE 04/03/2022 https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-la-covid-19-periode-du-11-02-2022-au-24-02-2022 2022 false false false France French mRNA Vaccine mRNA Vaccines 2019-nCoV Vaccine mRNA-1273 BNT162 Vaccine drug information pharmacovigilance adverse drug reaction reporting systems france vaccination Drug-Related side effects and adverse reactions drug monitoring mRNA vaccine Administration of vaccine product containing only severe acute respiratory syndrome
coronavirus 2 antigen (procedure) Covid-19 vaccines COVID-19 COVID-19 Vaccines
--- PUBLIÉ LE 18/03/2022 https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-la-covid-19-periode-du-25-02-2022-au-10-03-2022 2022 false false false France French mRNA Vaccines 2019-nCoV Vaccine mRNA-1273 BNT162 Vaccine brachial plexus neuritis anemia, hemolytic, autoimmune drug information pharmacovigilance adverse drug reaction reporting systems france vaccination Drug-Related side effects and adverse reactions drug monitoring Administration of vaccine product containing only severe acute respiratory syndrome
coronavirus 2 antigen (procedure) Covid-19 vaccines COVID-19 COVID-19 Vaccines
--- PUBLIÉ LE 01/04/2022 https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-la-covid-19-periode-du-11-03-2022-au-24-03-2022 2022 false false false France French mRNA Vaccines 2019-nCoV Vaccine mRNA-1273 BNT162 Vaccine drug information pharmacovigilance adverse drug reaction reporting systems france vaccination Drug-Related side effects and adverse reactions drug monitoring Administration of vaccine product containing only severe acute respiratory syndrome
coronavirus 2 antigen (procedure) Covid-19 vaccines COVID-19 COVID-19 Vaccines
--- PUBLIÉ LE 15/04/2022 https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-la-covid-19-periode-du-25-03-2022-au-07-04-2022 2022 false false false France French mRNA Vaccines 2019-nCoV Vaccine mRNA-1273 BNT162 Vaccine vasculitis drug information pharmacovigilance adverse drug reaction reporting systems france vaccination Drug-Related side effects and adverse reactions drug monitoring Administration of vaccine product containing only severe acute respiratory syndrome
coronavirus 2 antigen (procedure) Covid-19 vaccines COVID-19 COVID-19 Vaccines
--- PUBLIÉ LE 27/12/2022 https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-la-covid-19-periode-du-25-11-2022-au-22-12-2022 2022 false false false France French mRNA Vaccine mRNA Vaccines 2019-nCoV Vaccine mRNA-1273 BNT162 Vaccine NVX-CoV2373 adjuvated lipid nanoparticle drug information pharmacovigilance adverse drug reaction reporting systems france vaccination Drug-Related side effects and adverse reactions drug monitoring mRNA vaccine Administration of vaccine product containing only severe acute respiratory syndrome
coronavirus 2 antigen (procedure) Covid-19 vaccines COVID-19 COVID-19 Vaccines
--- PUBLIÉ LE 01/08/2022 https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-le-covid-19-periode-du-17-06-2022-au-21-07-2022 2022 false false false France French mRNA Vaccines 2019-nCoV Vaccine mRNA-1273 BNT162 Vaccine pericarditis drug information pharmacovigilance adverse drug reaction reporting systems france vaccination Drug-Related side effects and adverse reactions drug monitoring Administration of vaccine product containing only severe acute respiratory syndrome
coronavirus 2 antigen (procedure) Covid-19 vaccines COVID-19 COVID-19 Vaccines
--- https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-la-covid-19-periode-du-22-07-2022-au-08-09-2022 2022 false false false France French mRNA Vaccines 2019-nCoV Vaccine mRNA-1273 BNT162 Vaccine drug information pharmacovigilance adverse drug reaction reporting systems france vaccination Drug-Related side effects and adverse reactions drug monitoring Administration of vaccine product containing only severe acute respiratory syndrome
coronavirus 2 antigen (procedure) Covid-19 vaccines COVID-19 COVID-19 Vaccines
--- https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-le-covid-19-periode-du-2-09-2022-au-29-09-2022 2022 false false false France French mRNA Vaccines 2019-nCoV Vaccine mRNA-1273 BNT162 Vaccine drug information pharmacovigilance adverse drug reaction reporting systems france vaccination Drug-Related side effects and adverse reactions drug monitoring Administration of vaccine product containing only severe acute respiratory syndrome
coronavirus 2 antigen (procedure) Covid-19 vaccines COVID-19 COVID-19 Vaccines
--- https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-le-covid-19-periode-du-30-09-2022-au-20-10-2022 2022 false false false France French mRNA Vaccines 2019-nCoV Vaccine mRNA-1273 BNT162 Vaccine menorrhagia drug information pharmacovigilance adverse drug reaction reporting systems france vaccination Drug-Related side effects and adverse reactions drug monitoring Administration of vaccine product containing only severe acute respiratory syndrome
coronavirus 2 antigen (procedure) Covid-19 vaccines COVID-19 COVID-19 Vaccines
--- https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-la-covid-19-periode-du-21-10-2022-au-24-11-2022 2022 false false false France French mRNA Vaccines 2019-nCoV Vaccine mRNA-1273 BNT162 Vaccine drug information pharmacovigilance adverse drug reaction reporting systems france vaccination Drug-Related side effects and adverse reactions drug monitoring Administration of vaccine product containing only severe acute respiratory syndrome
coronavirus 2 antigen (procedure) Covid-19 vaccines COVID-19 COVID-19 Vaccines
--- PUBLIÉ LE 31/05/2022 https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-la-covid-19-periode-du-06-05-2022-au-23-05-2022 2022 false false false France French mRNA Vaccines 2019-nCoV Vaccine mRNA-1273 BNT162 Vaccine summary of product characteristics package leaflet drug information pharmacovigilance adverse drug reaction reporting systems france vaccination Drug-Related side effects and adverse reactions drug monitoring Administration of vaccine product containing only severe acute respiratory syndrome
coronavirus 2 antigen (procedure) Covid-19 vaccines COVID-19 COVID-19 Vaccines